Moderna Inc (MRNA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $90.38B
Last updated: Nov 17, 2026 at 11:06 AM ET
Moderna Inc (MRNA) Stock Forecast
Analysts expect Moderna (MRNA) to earn -$7.37 per share in the fiscal year ending Dec 31, 2026, on revenue of $2.41B. Of 23 analysts, 4 rate the stock Buy or Strong Buy, 15 Hold and 4 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 4 estimates for the fiscal year ending Dec 31, 2026 were revised up and 4 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 23 ratings average 3.04, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 17% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 4.3% |
| Buy | 3 | 13.0% |
| Hold | 15 | 65.2% |
| Sell | 2 | 8.7% |
| Strong Sell | 2 | 8.7% |
- Consensus
- Hold
- Total analysts
- 23
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 10.8%.
- Fiscal year ending Dec 31, 2026
- -$7.37
- EPS consensus, revenue $2.41B
- Fiscal year ending Dec 31, 2027
- -$4.34
- EPS consensus, revenue $2.67B
- Next report
- Feb 11, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$7.37 | -$9.06 to -$4.77 | 19 | $2.41B | $2.13B to $3.17B | 17 |
| Dec 31, 2027 | -$4.34 | -$5.96 to -$2.12 | 20 | $2.67B | $2.10B to $3.53B | 21 |
Quarterly Estimates
The EPS consensus rises from -$2.39 for the quarter ending Dec 31, 2026 to -$1.65 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$2.39 | -$4.20 to -$1.78 | 20 | $556.23M | $458.64M to $674.23M | 18 |
| Mar 31, 2027 | -$1.65 | -$2.19 to -$0.93 | 6 | $281.41M | $77.00M to $462.00M | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 9 upward and 8 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 4 | 4 |
| Fiscal year ending Dec 31, 2027 | 5 | 3 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$8.58.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$7.37 | -$8.49 | -$8.39 | -$8.38 | -$8.58 | N/A |
| Fiscal year ending Dec 31, 2027 | -$4.34 | -$4.90 | -$4.78 | -$4.79 | -$4.91 | N/A |
| Quarter ending Mar 31, 2027 | -$1.65 | -$1.85 | -$1.85 | -$1.85 | -$1.85 | N/A |
Frequently Asked Questions About MRNA
What is the MRNA stock forecast?
Consensus analyst estimates put Moderna's EPS at -$7.37 for the fiscal year ending Dec 31, 2026, on revenue of $2.41B. The consensus rating from 23 analysts is Hold.
How do analysts rate MRNA stock?
Of 23 analysts covering Moderna, 1 rates it Strong Buy, 3 Buy, 15 Hold, 2 Sell and 2 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from MRNA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$7.37, with estimates from -$9.06 to -$4.77 from 19 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$4.34, with estimates from -$5.96 to -$2.12 from 20 analysts.
What revenue do analysts expect from Moderna next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $2.41B, with estimates from $2.13B to $3.17B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $2.67B, with estimates from $2.10B to $3.53B.
How many analysts cover MRNA?
23 analysts rate Moderna stock, and 19 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
MRNA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors